Shared scheme for assessing drugs for multiple sclerosis: Why are eyes tightly shut to considering causes other than autoimmunity?

Publisher Website

29 May 2003

journal article
Published by BMJ in BMJ

Vol. 326 (7400), 1213
https://doi.org/10.1136/bmj.326.7400.1213

Abstract

Footnotes AC is supported by the Barclay Research Trust in the University of Glasgow. Competing interests None declared.

Keywords

This publication has 3 references indexed in Scilit:

Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis
BMJ, 2003
Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis
Brain, 2003
Effective clinical innovation: an ethical imperative
The Lancet, 2002

Cited by 1 article